Financial Survey: Evotec (NASDAQ:EVO) versus InterCure (NASDAQ:INCR)

Evotec (NASDAQ:EVO) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Evotec and InterCure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evotec	N/A	N/A	N/A
InterCure	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current recommendations for Evotec and InterCure, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	0	0	3	0	3.00
InterCure	0	0	0	0	N/A

Evotec currently has a consensus target price of $14.00, indicating a potential upside of 167.69%. Given Evotec’s higher probable upside, analysts clearly believe Evotec is more favorable than InterCure.

Insider and Institutional Ownership

5.8% of Evotec shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Evotec has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500.

Valuation & Earnings

This table compares Evotec and InterCure’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$791.73 million	2.34	-$185.07 million	N/A	N/A
InterCure	$115.83 million	1.05	$13.36 million	$0.13	20.54

InterCure has lower revenue, but higher earnings than Evotec.

Summary

Evotec beats InterCure on 4 of the 7 factors compared between the two stocks.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.